Hemispherx BioPharma, Inc (NYSEAMERICAN:HEB) Director Buys $38,998.31 in Stock

Hemispherx BioPharma, Inc (NYSEAMERICAN:HEB) Director William M. Mitchell purchased 9,677 shares of the stock in a transaction dated Friday, June 21st. The stock was purchased at an average price of $4.03 per share, with a total value of $38,998.31. Following the completion of the acquisition, the director now directly owns 20,838 shares in the company, valued at approximately $83,977.14. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Shares of HEB opened at $4.37 on Thursday. Hemispherx BioPharma, Inc has a 12 month low of $3.62 and a 12 month high of $14.81.

Hemispherx BioPharma (NYSEAMERICAN:HEB) last issued its quarterly earnings data on Thursday, May 16th. The specialty pharmaceutical company reported ($3.08) EPS for the quarter.

A number of equities research analysts have recently weighed in on HEB shares. Ascendiant Capital Markets set a $44.00 price target on Hemispherx BioPharma and gave the company a “buy” rating in a report on Friday, May 17th. Maxim Group started coverage on Hemispherx BioPharma in a report on Friday, June 14th. They issued a “buy” rating and a $8.00 price target for the company.

About Hemispherx BioPharma

Hemispherx Biopharma, Inc, a specialty pharmaceutical company, engages in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders in the United States. The company's products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and Ampligen for the treatment of chronic fatigue syndrome (CFS).

See Also: What is the QQQ ETF?

Insider Buying and Selling by Quarter for Hemispherx BioPharma (NYSEAMERICAN:HEB)

Receive News & Ratings for Hemispherx BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemispherx BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.